<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Preeclampsia: Prevention
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Preeclampsia: Prevention
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Preeclampsia: Prevention
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Phyllis August, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Arun Jeyabalan, MD, MSCR
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles J Lockwood, MD, MHCM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Vanessa A Barss, MD, FACOG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 26, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Preeclampsia refers to a syndrome characterized by the new onset of hypertension plus proteinuria, end-organ dysfunction, or both after 20 weeks of gestation in a previously normotensive individual  (
         <a class="graphic graphic_table graphicRef79977" href="/z/d/graphic/79977.html" rel="external">
          table 1
         </a>
         ). In individuals with preexisting (chronic) hypertension, accelerating hypertension plus proteinuria, end-organ dysfunction, or both after 20 weeks suggests superimposed preeclampsia.
        </p>
        <p>
         Preeclampsia is a common risk factor for maternal and perinatal morbidity and mortality worldwide. Standard prenatal care, including close follow-up of high-risk patients after midgestation, increases the chance that preeclampsia will be detected early in the course of disease. Early diagnosis followed by appropriate management, including delivery, may prevent some of the serious sequelae of the disease, such as eclamptic seizures and multiorgan failure.
        </p>
        <p>
         Since there is no curative treatment other than delivery, an intervention that could prevent preeclampsia would have a significant impact on maternal and neonatal health worldwide. Many different strategies to prevent preeclampsia have been investigated in randomized trials. It is not surprising that most simple approaches have been unsuccessful, given the complexities in pathogenesis and the likelihood that multiple etiologies or pathways result in the clinical syndrome. Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis is the most useful preventive pharmacologic intervention, but the magnitude of benefit is variable and depends on a number of factors.
        </p>
        <p>
         This topic will review several interventions that have been evaluated for prevention of preeclampsia. Other important aspects of preeclampsia are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6814.html" rel="external">
          "Preeclampsia: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6825.html" rel="external">
          "Preeclampsia: Antepartum management and timing of delivery"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6760.html" rel="external">
          "Preeclampsia: Pathogenesis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6750.html" rel="external">
          "Early pregnancy prediction of preeclampsia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3896379459">
         <span class="h1">
          EFFECTIVE INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h2">
          Low-dose aspirin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         reduces the frequency of preeclampsia, as well as related adverse pregnancy outcomes (preterm birth, growth restriction), by approximately 10 to 20 percent when taken by patients at moderate to high risk of the disease. It has an excellent maternal/fetal safety profile, thus it is a reasonable preventive strategy for these patients. (See
         <a class="local">
          'Safety'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H803272901">
         <span class="h3">
          Rationale
         </span>
         <span class="headingEndMark">
          —
         </span>
         The observation that preeclampsia is associated with increased platelet turnover and increased platelet-derived thromboxane levels led to randomized trials evaluating low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy in patients thought to be at increased risk of the disease [
         <a href="#rid1">
          1-6
         </a>
         ]. As opposed to higher dose aspirin therapy, low-dose aspirin (60 to 150 mg/day) diminishes platelet thromboxane synthesis while maintaining vascular wall prostacyclin synthesis [
         <a href="#rid6">
          6-8
         </a>
         ]. Although not well studied, the beneficial effect of low-dose aspirin for prevention of preeclampsia may also be partly related to modulation of inflammation, which is exaggerated in patients with preeclampsia [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2318983441">
         <span class="h3">
          Evidence of efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence from meta-analyses of randomized trials clearly shows that prophylactic administration of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to pregnant patients has a modest ability (RR 0.57 to 0.92) to reduce the risk of developing preeclampsia and its sequelae [
         <a href="#rid10">
          10
         </a>
         ]. For example:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2019 meta-analysis reported the following main outcomes for prophylactic use of antiplatelet agents, primarily low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         (50 to 162 mg per day), compared with either placebo or no antiplatelet agent (74 trials, &gt;40,000 patients across the range of low, moderate, or high risk of preeclampsia) [
         <a href="#rid11">
          11
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction in proteinuric preeclampsia – 16 fewer cases per 1000 patients treated (risk ratio [RR] 0.82, 95% CI 0.77-0.88). The analysis did not specifically evaluate occurrence of preterm versus term preeclampsia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction in fetal or neonatal death – 5 fewer deaths per 1000 patients treated (RR 0.85, 95% CI 0.76-0.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction in overall preterm birth &lt;37 weeks – 16 fewer cases per 1000 patients treated (RR 0.91, 95% CI 0.87-0.95).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction in small for gestational age newborns – 7 fewer cases per 1000 patients treated (RR 0.84, 95% CI 0.76-0.92).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reduction in composite serious adverse maternal and neonatal outcomes – 20 fewer cases per 1000 patients treated (RR 0.90, 95% CI 0.85-0.96).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The intervention may have slightly increased the risk of postpartum hemorrhage &gt;500 mL (RR 1.06, 95% CI 1.00-1.12) but did not have a statistically significant effect on risk of abruption (RR 1.21, 95% CI 0.95-1.54).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although others have shown that preterm births &lt;32 weeks decreased by approximately 60 percent (1.2 versus 2.9 percent, odds ratio [OR] 0.42, 95% CI 0.19-0.93) [
         <a href="#rid12">
          12
         </a>
         ], this meta-analysis did not find a large or clear reduction (RR 0.92, 95% CI 0.83-1.02) [
         <a href="#rid11">
          11
         </a>
         ]. It also found that antiplatelet agents probably make little or no difference in the risk of HELLP syndrome (hemolysis, elevated liver enzymes, low platelets; RR 0.77, 95% CI 0.44-1.36), severe maternal morbidity (RR 1.00, 95% CI 0.72-1.39), or admission to a newborn special care unit (RR 0.95, 95% CI 0.90-1.00) [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2021 meta-analysis by the United States Preventive Services Task Force (USPSTF) reported similar data: lower risk of preeclampsia (RR 0.85, 95% CI 0.75-0.95), perinatal mortality (RR 0.79, 95% CI 0.66-0.96), preterm birth &lt;37 weeks (RR 0.80, 95% CI 0.67-0.95), fetal growth restriction (RR 0.82, 95% CI 0.68-0.99), and no significant increase in bleeding related harms [
         <a href="#rid13">
          13
         </a>
         ]. In the larger trials, absolute risk reductions for preeclampsia ranged from -1 to -6 percent and absolute risk reduction for perinatal mortality ranged from -0.5 to -1.1 percent. The analysis did not specifically evaluate occurrence of preterm versus term preeclampsia. Trial participants were individuals at increased risk based on clinical risk factors or measurements associated with higher disease incidence than in the general population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2018 meta-analysis specifically evaluating the effects of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         on development of preterm versus term preeclampsia, there was a significant reduction in occurrence of preterm preeclampsia (before 37 weeks of gestation: RR 0.62, 95% CI 0.45-0.87) but not at term (RR 0.92, 95% CI 0.70-1.21) [
         <a href="#rid14">
          14
         </a>
         ]. In the largest trial (ASPRE), high-risk individuals were identified by multivariable first-trimester screening and randomly assigned to receive aspirin (150 mg daily) or placebo starting at 11 to 13 weeks of gestation and continuing until 36 weeks of gestation [
         <a href="#rid15">
          15
         </a>
         ]. The aspirin group had a 62 percent reduction in preterm preeclampsia &lt;37 weeks (1.6 versus 4.3 percent, OR 0.38, 95% CI 0.20-0.74); the reduction in term preeclampsia was not significant (6.6 versus 7.2 percent, OR 0.95, 95% CI 0.57-1.57).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H65619565">
         <span class="h3">
          Candidates
         </span>
        </p>
        <p class="headingAnchor" id="H1424609381">
         <span class="h4">
          Selecting patients at high risk of developing preeclampsia
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis for patients at high risk of developing preeclampsia, based on the evidence described above (See
         <a class="local">
          'Evidence of efficacy'
         </a>
         above.). The greatest benefit appears to be in patients at moderate to high risk of developing the disease [
         <a href="#rid11">
          11,15-23
         </a>
         ].
        </p>
        <p>
         There is some variation among international guidelines regarding the specific criteria that confer high and moderate risk  (
         <a class="graphic graphic_table graphicRef142323" href="/z/d/graphic/142323.html" rel="external">
          table 2
         </a>
         ). In the United States, the USPSTF high-risk criteria are typically used [
         <a href="#rid24">
          24
         </a>
         ] and endorsed by the American College of Obstetricians and Gynecologists (ACOG) [
         <a href="#rid25">
          25
         </a>
         ]. The incidence of preeclampsia is estimated to be at least 8 percent for pregnant patients with
         <strong>
          any one of these
         </strong>
         <strong>
          high-risk factors
         </strong>
         :
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Previous pregnancy with preeclampsia, especially early onset and with an adverse outcome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Type 1 or 2 diabetes mellitus.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic hypertension.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multifetal gestation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Kidney disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune disease with potential vascular complications (antiphospholipid syndrome, systemic lupus erythematosus).
        </p>
        <p>
        </p>
        <p>
         Clinicians have expanded use of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to other conditions in which the incidence of preeclampsia is estimated to be at least 8 percent. These include sickle cell disease and inflammatory bowel disease.
        </p>
        <p>
         Although the USPSTF and ACOG have not addressed the 2017 American College of Cardiology/American Heart Association revised hypertension definitions with respect to pregnant patients, in a secondary analysis of patients with prior preeclampsia or pregestational diabetes, the subgroup of these high risk patients with stage I hypertension (systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg) had a high frequency of preeclampsia that was lower in those treated with low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis versus placebo (24 versus 39 percent) [
         <a href="#rid26">
          26
         </a>
         ]. The subgroup of normotensive high risk patients was at lower risk for preeclampsia, and the risk was similar in the aspirin and placebo groups (14.6 versus 15.1 percent). In patients with stage I hypertension and no other risk factors for preeclampsia, a potential beneficial effect of low-dose aspirin needs to be established in prospective trials before a recommendation for routine prophylaxis can be made.
        </p>
        <p>
         The management of patients with moderate risk factors is less straightforward. The USPSTF and ACOG recommend low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for preeclampsia prevention in patients with two or more moderate risk factors. The incidence of preeclampsia is estimated to be less than 8 percent in those with only one moderate risk factor, but increases with multiple moderate risk factors. Importantly, not all moderate risk factors are associated with the same magnitude of preeclampsia risk, and the frequency of these risk factors varies in different populations. In addition, the risk reduction benefits of low-dose aspirin have not been evaluated in each of these subgroups.
        </p>
        <p>
         We generally follow the USPSTF criteria and recommend low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for preeclampsia prevention to patients with
         <strong>
          two or more of the following
         </strong>
         <strong>
          moderate risk factors
         </strong>
         [
         <a href="#rid24">
          24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nulliparity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obesity (body mass index &gt;30 kg/m
         <sup>
          2
         </sup>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of preeclampsia in mother or sister.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age ≥35 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sociodemographic characteristics (Black persons, lower income level [recognizing that these are not biological factors]).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal risk factors (eg, previous pregnancy with low birth weight or small for gestational age newborn, previous adverse pregnancy outcome [eg, stillbirth], interval &gt;10 years between pregnancies).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In vitro conception
        </p>
        <p>
        </p>
        <p>
         The USPSTF and ACOG also suggest considering low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for patients with only one moderate risk factor [
         <a href="#rid24">
          24
         </a>
         ]. This consideration was motivated by concerns for disparities in outcomes for people with less access to medical care and to potentially reduce the racial disparity in the prevalence of preeclampsia in disadvantaged groups.
        </p>
        <p>
         Even though nulliparous patients are the group comprising the largest proportion of preeclampsia cases, nulliparity alone is not an indication for prophylaxis. A meta-analysis of trials limited to low-risk nulliparous patients found no benefit [
         <a href="#rid27">
          27
         </a>
         ] and major trials limited to unselected nulliparous patients also found little or no benefit from prophylactic low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy [
         <a href="#rid28">
          28,29
         </a>
         ].
        </p>
        <p>
         Other conditions (eg, thrombotic thrombocytopenic purpura [
         <a href="#rid30">
          30,31
         </a>
         ], use of assisted reproductive techniques [
         <a href="#rid32">
          32,33
         </a>
         ]) may also confer high or moderate risk for preeclampsia, but available data are limited. We individualize use of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in such patients. (See
         <a class="medical medical_review" href="/z/d/html/101762.html" rel="external">
          "Immune TTP: Management following recovery from an acute episode and during remission", section on 'Pregnancy after an episode of TTP'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2019808479">
         <span class="h4">
          Other considerations
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Role of universal prophylaxis
         </strong>
         – ACOG has opined that in practice settings in which the majority of patients are at high or moderate risk for preeclampsia and would therefore be candidates for low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis, universal implementation (eg, offering low-dose aspirin to all patients) may be medically reasonable [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          High-risk multiparous patients with no history of preeclampsia
         </strong>
         – Guidelines have not specifically addressed the management of multiparous patients who are at high risk for preeclampsia based on the risk factors described above, but who did
         <strong>
          not
         </strong>
         develop preeclampsia in previous pregnancies even though they did not take low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for preeclampsia prevention. We suggest low-dose aspirin prophylaxis for these patients as a prudent approach.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of algorithms for candidate selection
         </strong>
         – Multimarker algorithms for identifying patients at high risk for preeclampsia have been published [
         <a href="#rid34">
          34-38
         </a>
         ], but none are widely used in the United States, as they have not been validated in a variety of unselected populations. These algorithms typically include biochemical and imaging results, as well as historical risk factors. (See
         <a class="medical medical_review" href="/z/d/html/6750.html" rel="external">
          "Early pregnancy prediction of preeclampsia", section on 'Risk prediction models'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of low-dose
         </strong>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         <strong>
          for treatment of established preeclampsia
         </strong>
         – Low-dose aspirin appears to be of little or no benefit in patients who already have developed preeclampsia [
         <a href="#rid6">
          6,39,40
         </a>
         ]. At this late stage, aspirin does not prevent progression to more severe disease and may exacerbate bleeding in patients with thrombocytopenia related to preeclampsia/HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2205590804">
         <span class="h3">
          Timing of initiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         We initiate low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for preeclampsia prevention at ≥12 weeks of gestation, and ideally prior to 16 weeks [
         <a href="#rid16">
          16,24,25,41-43
         </a>
         ], although adverse effects from earlier initiation (eg, preconception) have not been consistently documented [
         <a href="#rid44">
          44,45
         </a>
         ] and others (eg, the International Federation of Gynecology and Obstetrics) recommend initiation of aspirin at 11 to 14 weeks [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Early therapy (before 16 weeks) may be important since the pathophysiologic features of preeclampsia develop early in pregnancy, weeks before clinical disease is apparent. However, available evidence is inconsistent about the benefits of early initiation of therapy (particularly before 11 weeks [
         <a href="#rid47">
          47
         </a>
         ]), possibly because
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         has major effects on prostacyclin production and endothelial function throughout gestation [
         <a href="#rid48">
          48
         </a>
         ]. If aspirin is not initiated at the end of the first trimester, initiation after 16 weeks (but before symptoms develop) may also be effective [
         <a href="#rid18">
          18
         </a>
         ]. The majority of trials have initiated therapy before 28 weeks.
        </p>
        <p>
         No trials have directly compared early versus late initiation of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         therapy for preeclampsia prevention.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the 2019 meta-analysis discussed above, data suggested a slight benefit to initiating
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         before rather than after 20 weeks of gestation (RR 0.85 and 0.90 at &lt;16 and 16 to 19 weeks versus RR 0.99, 0.88, and 0.95 at 20 to 23, 24 to 27, and ≥28 weeks, respectively), but the confidence intervals for the risk ratios at the various gestational ages overlapped; thus, whether a real difference exists is uncertain [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H237061470">
         <span class="h3">
          Dose
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Typically
         </strong>
         <strong>
          75 to 162 mg
         </strong>
         – There is no consensus regarding the optimal dose of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for preeclampsia prevention. We use 81 mg daily, which is the commercially available dose in the United States and has proven efficacy. Based on the data described below, some authorities have advocated a higher dose of aspirin (100 to 150 mg) daily, which is also reasonable. In the United States, the higher dosing has been achieved by taking one and one-half 81 mg tablets daily (121.5 mg), or one 81 mg pill on "odd" days and two 81 mg pills on "even" days. Although no trials have evaluated the efficacy of doses &gt;150 mg, which could be achieved easily by taking two 81 mg tablets or splitting a 325 mg tablet in half, the 162 mg dose is one of the pragmatic options suggested by the Society of Obstetricians and Gynaecologists of Canada [
         <a href="#rid43">
          43
         </a>
         ] and others [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For prevention of myocardial infarction and stroke in nonpregnant individuals,
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         appears to be equally effective at doses between 75 and 325 mg/day. (See
         <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">
          "Aspirin in the primary prevention of cardiovascular disease and cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to note that there has been no head-to-head comparison or individual patient data meta-analysis comparing &lt;100 mg versus ≥100 mg
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         doses; either of these research methods would provide more robust data regarding optimal dose.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 2017 meta-analysis suggested a dose-response effect for the prevention of preeclampsia, severe preeclampsia, and fetal growth restriction, with higher doses associated with a greater risk reduction [
         <a href="#rid23">
          23
         </a>
         ]. In the ASPRE trial, 150 mg
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         was used with a significant risk reduction of preterm preeclampsia [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A 2018 meta-analysis in which subgroup analyses were available found that
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         reduced the risk of preeclampsia only when it was initiated at ≤16 weeks of gestation and at a daily dose of ≥100 mg [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In the 2019 meta-analysis discussed above, trials using doses &gt;75 mg appeared to show a greater risk reduction for preeclampsia than trials using doses &lt;75 mg, but further studies are warranted since the overall data were not conclusive [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Variations in dosing regimens among studies are at least partly based on different formulations available in various regions of the world.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Morning versus evening administration
         </strong>
         – Some authors believe that
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         may be more effective if taken at bedtime [
         <a href="#rid49">
          49,50
         </a>
         ]; however, specifying timing of administration is not standard practice, and nighttime dosing may increase gastric irritation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Importance of good adherence
         </strong>
         – Good adherence with therapy is important; adherence &lt;90 percent may not be effective [
         <a href="#rid51">
          51,52
         </a>
         ]. Strategies to improve medication adherence include patient education, daily count-type pillboxes, and telemonitoring or mobile health applications for reminding [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H572782449">
         <span class="h3">
          Timing of discontinuation
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no consensus on the optimal timing of
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         discontinuation. In our practice, we continue low-dose aspirin until delivery. Some advocate discontinuation at 36 weeks of gestation or 5 to 10 days before expected delivery to diminish the risk of bleeding during delivery [
         <a href="#rid2">
          2,5,54
         </a>
         ]; however, no adverse maternal or fetal effects related to use of low-dose aspirin at delivery have been proven.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A randomized trial evaluated early
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         discontinuation. Patients considered at high risk of preterm preeclampsia (≥1/170) based on a first-trimester screening algorithm were placed on aspirin 150 mg daily before 14 weeks of gestation [
         <a href="#rid55">
          55
         </a>
         ]. At 24 to 28 weeks of gestation, those with an sFlt-1:PlGF ratio ≤38 (ie, the level that excludes preeclampsia) stopped taking aspirin. The risk of preterm preeclampsia was similar for both groups (early discontinuation group: 1.48 percent [7 in 473] versus 1.73 percent [8 in 463] in the control group; RR 0.86, 95% CI 0.31-2.34); the risk of term preeclampsia was also similar for both groups (early discontinuation: 6.3 versus 8.6 percent in the control group; RR 0.73, 95% CI 0.47-1.16). The discontinuation group had less minor antepartum bleeding (7.6 versus 12.3 percent; RR 0.62, 95% CI 0.42-0.92), but differences in the risks of all other adverse outcomes were not statistically significant. These findings warrant further study. They are not generalizable to other populations, such as the United States, where a lower dose of aspirin (81 mg) is commonly used and the population is more diverse (eg, White participants accounted for 93 percent of the trial population). A laboratory test to measure sFlt-1:PlGF was first approved by the US Food and Drug Administration in mid 2023 for use in pregnant patients hospitalized for a hypertensive disorder of pregnancy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H175929321">
         <span class="h3">
          Safety
         </span>
         <span class="headingEndMark">
          —
         </span>
         The short-term safety of low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         use in the second and third trimesters is well established [
         <a href="#rid11">
          11,56
         </a>
         ], and it appears to be safe in the first trimester as well (ie, no demonstrable increase in rates of miscarriage or congenital anomalies) [
         <a href="#rid57">
          57,58
         </a>
         ]. Importantly, there is no clear increase in risk of fetal/neonatal intracranial bleeding (intraventricular hemorrhage: RR 0.99, 95% CI 0.72-1.36; other neonatal bleeding: RR 0.90, 95% CI 0.75-1.08; 20 trials, &gt;32,000 neonates), but a small absolute increase in risk of postpartum hemorrhage is likely (143 hemorrhages &gt;500 mL per 1000 patients, which represents 9 more hemorrhages per 1000 patients compared with nonuse of aspirin; RR 1.06, 95% CI 1.00-1.12) [
         <a href="#rid11">
          11
         </a>
         ]. The comparative safety of different doses has not been evaluated, but a trial comparing the 150 mg dose with placebo reported similar rates of maternal bleeding (eg, vaginal, nasal, skin bruising, abruption) in both groups, suggesting a low risk of maternal harm with the 150 mg dose [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
         Longer term safety data are limited. In a meta-analysis of data from the Collaborative Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          Aspirin
         </a>
         Study in Pregnancy (CLASP) and the Italian Study of Aspirin in Pregnancy (ISAP) trials, in utero exposure to low-dose aspirin for prophylaxis or treatment of preeclampsia or fetal growth restriction was associated with lower postneonatal mortality until age 12 months, fewer hospital visits for developmental delay at 12 months, and improved gross and fine motor function at 18 months [
         <a href="#rid59">
          59
         </a>
         ]. There were no differences in other neurodevelopmental outcomes (language, hearing and/or vision problems), respiratory problems, and the proportion of children with a short stature and/or low weight.
        </p>
        <p class="headingAnchor" id="H2935922252">
         <span class="h2">
          Treatment of chronic hypertension to lower blood pressure targets
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the 2022 Control of Mild Hypertension During Pregnancy Trial (CHAP), a strategy of treating pregnant patients with blood pressures ≥140/90 mmHg compared with a strategy of reserving treatment only for severe hypertension reduced the incidence of any preeclampsia (24.4 versus 31.1 percent; RR 0.79, 95% CI 0.69-0.89), preeclampsia with severe features (23.2 versus 29.1, RR 0.80, 95% CI 0.70-0.92), and medically-indicated preterm birth &lt;35 weeks (12.2 versus 16.7 percent; RR 0.73, 95% CI 0.60-0.89), as well as the development of severe hypertension in pregnancy (36.1 versus 44.3 percent; RR 0.82, 95% CI 0.74-0.90) [
         <a href="#rid60">
          60
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">
          "Chronic hypertension in pregnancy: Prenatal and postpartum care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1097986069">
         <span class="h2">
          Timed birth at 39 weeks in low-risk, nulliparous patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         The ARRIVE trial showed that low-risk nulliparas assigned to induction of labor at 39+0 to 39+4 weeks of gestation were less likely to develop a hypertensive disorder of pregnancy than those assigned to expectant management until 40+5 to 42+2 weeks (gestational hypertension or preeclampsia: 9.1 versus 14.1 percent; RR 0.64, 95% CI 0.56-0.74) [
         <a href="#rid61">
          61
         </a>
         ]. Results for gestational hypertension versus preeclampsia were not provided. We emphasize that this approach for prevention of preeclampsia requires shared decision-making, and available evidence is inadequate to extrapolate to other populations, such as high-risk and/or parous patients. The risks and spectrum of benefits of induction of labor at 39 weeks is discussed in detail separately (see
         <a class="medical medical_review" href="/z/d/html/4476.html" rel="external">
          "Induction of labor with oxytocin"
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3926506193">
         <span class="h1">
          POSSIBLY EFFECTIVE INTERVENTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis is the generally accepted therapy for prevention of preeclampsia. The following interventions have been either offered to a particular subgroup of patients, on a case-by-case basis to highly selected patients, or on an investigational basis.
        </p>
        <p class="headingAnchor" id="H3331389734">
         <span class="h2">
          Calcium supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Low dietary calcium intake is associated with hypertension in the general population. (See
         <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">
          "Diet in the treatment and prevention of hypertension", section on 'Other dietary interventions'
         </a>
         .)
        </p>
        <p>
         Pregnant individuals should achieve the recommended daily allowance (RDA) for elemental calcium through diet and/or supplements. In the United States, the RDA for elemental calcium is 1000 mg/day in pregnant, lactating, or nonpregnant females 19 to 50 years of age (1300 mg for girls 14 to 18 years of age). The United States female population in the reproductive age range has an average calcium intake of 950 mg/day; thus, most are candidates for modest supplementation, which may be supplied by a prenatal vitamin [
         <a href="#rid62">
          62
         </a>
         ]. However, individuals who have low dairy intake, other calcium deficient states, or live in an area of endemic calcium deficiency may benefit from higher calcium supplementation to reduce the risk of preeclampsia. (See
         <a class="medical medical_review" href="/z/d/html/453.html" rel="external">
          "Nutrition in pregnancy: Dietary requirements and supplements", section on 'Calcium and vitamin D'
         </a>
         .)
        </p>
        <p>
         In populations where baseline dietary calcium intake is low, the World Health Organization (WHO) recommends 1500 to 2000 mg elemental calcium supplementation per day divided into three doses for pregnant individuals to reduce the risk of preeclampsia, particularly among those at higher risk of developing hypertension (2.5 g of
         <a class="drug drug_general" data-topicid="9185" href="/z/d/drug information/9185.html" rel="external">
          calcium carbonate
         </a>
         or 4.75 g of
         <a class="drug drug_general" data-topicid="8829" href="/z/d/drug information/8829.html" rel="external">
          calcium citrate
         </a>
         contains approximately 1 g elemental calcium) [
         <a href="#rid63">
          63
         </a>
         ]. The WHO recommendation is based on positive results from systematic reviews (see following example), which should be interpreted with caution because of the possibility of small-study effect or publication bias.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2022 meta-analysis evaluated calcium supplementation versus placebo/no therapy for preeclampsia prevention (30 randomized trials; &gt;20,000 participants) [
         <a href="#rid64">
          64
         </a>
         ]. Seventeen trials included patients considered to be at high risk of developing preeclampsia, 24 trials included patients with low baseline calcium intake (&lt;900 mg/day), 18 trials used high-dose calcium supplementation (≥1 g elemental calcium/day), and six trials initiated calcium before 20 weeks of gestation but most of the remainder initiated the intervention soon after 20 weeks. Median adherence to calcium supplementation was &gt;80 percent. One-third of trials were at high risk of bias. Major findings were:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Calcium supplementation reduced the risk of developing preeclampsia (risk ratio [RR] 0.49, 95% CI 0.39-0.61). Other maternal and perinatal outcomes were not substantially different between the supplementation and placebo/no therapy groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The risk reduction for preeclampsia was statistically significant in patients with low baseline calcium intake (RR 0.45, 95% CI 0.35-0.58) but not in those with adequate baseline intake (RR 0.62, 95% CI 0.37-1.06).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The risk reduction occurred in low dose (&lt;1 g) and high dose (≥1) supplementation trials (low dose RR 0.49, 95% CI 36-65; high dose: RR 0.49, 95% CI 0.36-0.66).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The risk reduction with supplementation occurred in patients with low- and high-baseline preeclampsia risk (low risk: RR 0.46, 95% CI 0.42-0.76; high risk: RR 0.41, 95% CI 0.29-0.57).
        </p>
        <p>
        </p>
        <p>
         A subsequent randomized trial specifically evaluated low (500 mg) versus high (1500 mg) calcium supplementation in over 20,000 nulliparous pregnant people residing in two countries with low dietary calcium intake [
         <a href="#rid65">
          65
         </a>
         ]. Low-dose calcium supplementation was noninferior to high-dose calcium supplementation with respect to the risk of preeclampsia (India: 3 versus 3.6 percent, RR 0.84, 95% CI 0.68-1.03; Tanzania: 3.0 versus 2.7 percent, RR 1.90, 95% CI 0.88-1.36). These findings suggest that a single 500 mg supplement is sufficient to reduce the risk of preeclampsia and would be less cumbersome than the current WHO recommendation of 1500 to 2000 mg per day divided into three doses.
        </p>
        <p class="headingAnchor" id="H4260996288">
         <span class="h2">
          Prepregnancy weight loss and appropriate gestational weight gain
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients who are overweight or obese, prepregnancy weight loss has a variety of reproductive, pregnancy, and overall health benefits. In particular, cohort studies of females who underwent bariatric surgery suggest that weight loss in females with obesity significantly reduces the risk of preeclampsia [
         <a href="#rid66">
          66
         </a>
         ]. In addition, a cohort study of individuals with preeclampsia found weight loss between pregnancies reduced the risk of recurrent preeclampsia in those who were normal weight, overweight, or obese [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/433.html" rel="external">
          "Obesity in pregnancy: Complications and maternal management", section on 'Prepregnancy weight loss'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/411.html" rel="external">
          "Fertility and pregnancy after bariatric surgery", section on 'Preeclampsia and other hypertensive disorders of pregnancy'
         </a>
         .)
        </p>
        <p>
         Patients may reduce their risk of developing preeclampsia by not exceeding Institute of Medicine (now National Academy of Medicine) recommendations for gestational weight gain. Those who are overweight or obese are likely to benefit most [
         <a href="#rid68">
          68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/441.html" rel="external">
          "Gestational weight gain", section on 'Recommendations for gestational weight gain'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H303904410">
         <span class="h2">
          Exercise
         </span>
         <span class="headingEndMark">
          —
         </span>
         Exercise has several health benefits and is a potential strategy for reducing the risk of developing preeclampsia in individuals who are not candidates for low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis, but exercise for this indication warrants further investigation. In a meta-analysis of randomized trials of exercise-related interventions in selected pregnant individuals, exercise-only interventions generally reduced the odds of developing preeclampsia (odds ratio [OR] 0.59, 95% CI 0.37-0.94) [
         <a href="#rid69">
          69
         </a>
         ]. Some benefit began to accrue when exercise was performed at a frequency of at least three days/week or at least 25 minutes per session, but 140 minutes per week of brisk walking, water aerobics, stationary cycling, or resistance training would be required for a 25 percent reduction in preeclampsia. Surprisingly, interventions combining exercise and cointerventions (such as counseling) were less effective than exercise alone (OR 0.97, CI 0.78-1.21), possibly because patients in the counseling trials were often unsupervised during exercise and poorly compliant.
        </p>
        <p>
         In another meta-analysis of randomized trials comparing supervised exercise during pregnancy with standard antenatal care or unsupervised exercise, the intervention reduced the incidence of hypertensive disorders of pregnancy (3 versus 5 percent; OR 0.54, 95% CI 0.40-0.72) [
         <a href="#rid70">
          70
         </a>
         ]. Structured exercise (combination of aerobic, strength, and flexibility workouts) and yoga were both effective. (See
         <a class="medical medical_review" href="/z/d/html/412.html" rel="external">
          "Exercise during pregnancy and the postpartum period", section on 'Prescribing exercise for pregnant individuals'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2776438505">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients undergoing fertility therapy with in vitro fertilization or ovulation induction alone, various techniques can be employed to reduce the chances of multiple gestation, especially triplets or more. (See
         <a class="medical medical_review" href="/z/d/html/7417.html" rel="external">
          "Strategies to control the rate of high order multiple gestation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H172313575">
         <span class="h1">
          INVESTIGATIONAL APPROACHES
         </span>
        </p>
        <p class="headingAnchor" id="H3874714871">
         <span class="h2">
          Statins
         </span>
         <span class="headingEndMark">
          —
         </span>
         Statins are generally discontinued in pregnancy, with some exceptions, such as patients with homozygous familial hypercholesterolemia or established cardiovascular disease and at very high risk of myocardial infarction or stroke [
         <a href="#rid71">
          71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4564.html" rel="external">
          "Statins: Actions, side effects, and administration", section on 'Risks in pregnancy and breastfeeding'
         </a>
         .)
        </p>
        <p>
         Endothelial dysfunction and inflammation are key components of both adult cardiovascular disease and preeclampsia. Because inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (ie, statins) are effective for primary and secondary prevention of cardiovascular mortality and morbidity, these drugs may also reduce the risk of preeclampsia. Data from animal studies [
         <a href="#rid72">
          72-76
         </a>
         ] and a single small pilot trial in humans [
         <a href="#rid77">
          77
         </a>
         ] support this hypothesis. However, in a multicenter randomized trial of over 1100 patients with singleton pregnancies at high risk for term preeclampsia,
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         20 mg daily beginning at 35+0 to 36+6 weeks and continuing until birth did not reduce the incidence of preeclampsia (hazard ratio 1.08, 95% CI 0.78-1.49) or other adverse pregnancy outcomes compared with placebo [
         <a href="#rid78">
          78
         </a>
         ]. The justification for the very short duration of therapy in this trial is not clear, and few preventive trials of any strategy have initiated therapy at this late gestational age; therefore, the negative results are not surprising. Appropriately powered randomized trials are warranted to determine whether earlier initiation of therapy, use of higher doses, or use of more potent statins might be effective [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2761705449">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The placenta of patients with preeclampsia displays characteristic features of uteroplacental ischemia, including increased syncytial knots and intervillous fibrin, distal villous hypoplasia, villous infarcts, decidual necrosis, and spiral artery abnormalities including acute atherosis, mural hypertrophy, and luminal thrombosis/fibrous obliteration. (See
         <a class="medical medical_review" href="/z/d/html/2282.html" rel="external">
          "The placental pathology report", section on 'Preeclampsia'
         </a>
         .)
        </p>
        <p>
         The use of prophylactic anticoagulation in selected high-risk patients, particularly those with known thrombophilic genetic variants plus a history of placenta-mediated adverse pregnancy outcome (eg, early severe preeclampsia) has been suggested to prevent recurrence [
         <a href="#rid80">
          80-85
         </a>
         ]. However, available limited data do not support this practice.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a 2016 meta-analysis using individual patient data from eight randomized trials of low molecular weight heparin (LMWH) therapy versus no LMWH for patients with any prior placenta-mediated pregnancy complications (term or preterm preeclampsia, late pregnancy loss, placental abruption, birth of a small for gestational age [SGA] neonate), the intervention did not significantly reduce the incidence of the primary composite outcome (early-onset or severe preeclampsia, SGA newborn &lt;5
         <sup>
          th
         </sup>
         percentile, abruption, pregnancy loss ≥20 weeks of gestation): 62/444 (14 percent) versus 95/443 (22 percent), absolute difference -8 percent, 95% CI -17.3 to 1.4, relative risk (RR) 0.64, 95% CI 0.36-1.11 [
         <a href="#rid86">
          86
         </a>
         ]. There were also no significant differences in the secondary outcomes of preeclampsia, severe preeclampsia, early-onset preeclampsia, and severe or early-onset preeclampsia. An unexplained observation from this meta-analysis was that the results obtained from single-center trials contrasted starkly with those from the multicenter trials, with the former demonstrating significant benefit from LMWH while the latter did not.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with hereditary thrombophilias, another meta-analysis found that use of LMWH did not improve live birth weight or other pregnancy outcomes compared with low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         alone; however, the findings were based on a few trials with methodological limitations [
         <a href="#rid87">
          87
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Since publication of these meta-analyses, two additional multicenter, randomized trials were published in which low molecular heparin in high-risk patients did not reduce preeclampsia recurrence and other adverse pregnancy outcomes [
         <a href="#rid88">
          88,89
         </a>
         ]. Although these data do not demonstrate benefits of LMWH, concerns remain regarding heterogeneity between single-center and multicenter trials, inclusion of different placenta-mediated processes and phenotypes that may have different pathogenic pathways, differences in LMWH treatment protocols (dose, initiation/duration of treatment, combination therapy), analysis of multiple subgroups, multiple assessed outcomes, and possible lack of power to answer all of the relevant clinical questions, thus further investigation to needed to address these deficiencies.
        </p>
        <p class="headingAnchor" id="H4019167659">
         <span class="h2">
          Metformin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          Metformin
         </a>
         is an oral hypoglycemic agent used to treat type 2 diabetes and gestational diabetes. It has multiple sites of action and pre-clinical studies indicate a reduction in secretion of anti-angiogenic factors from the placenta and mitigation of endothelial dysfunction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In pregnant patients with obesity but no diabetes, a placebo-controlled randomized trial evaluating use of
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         to decrease maternal and fetal weight gain found it reduced the rate of preeclampsia by 76 percent (odds ratio [OR] 0.24, 95% CI 0.10-0.61) [
         <a href="#rid90">
          90
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In high-risk insulin-resistant patients, a meta-analysis of trials comparing
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         with insulin also demonstrated a reduction in preeclampsia (OR 0.68, 95% CI 0.48-0.95), but no difference in the overall rate of hypertensive disorders of pregnancy (OR 0.86, 95% CI 0.33-2.26) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Subsequently, in a multicenter randomized trial that assigned 502 pregnant patients with type 2 diabetes to receive either
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         or placebo added to insulin, metformin did not reduce the combined outcome of gestational hypertension, worsening chronic hypertension, or preeclampsia (23 percent in both groups) [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H904179749">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of other agents are being investigated for primary prevention of preeclampsia or secondary prevention/mitigation of adverse outcomes in established preeclampsia [
         <a href="#rid93">
          93
         </a>
         ]. In addition to those mentioned above,
         <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">
          omeprazole
         </a>
         and
         <a class="drug drug_general" data-topicid="9963" href="/z/d/drug information/9963.html" rel="external">
          sulfasalazine
         </a>
         are being studied in clinical trials.
        </p>
        <p class="headingAnchor" id="H168219868">
         <span class="h1">
          PROBABLY INEFFECTIVE INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2475169678">
         <span class="h2">
          Vitamin C and E supplements
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend not prescribing antioxidant supplementation with
         <a class="drug drug_general" data-topicid="9776" href="/z/d/drug information/9776.html" rel="external">
          vitamin C
         </a>
         and/or E for prevention of preeclampsia. Multiple large, randomized, multicenter trials including patients at both high and low risk of developing preeclampsia have consistently demonstrated that it is not effective [
         <a href="#rid94">
          94-101
         </a>
         ]. Meta-analyses of nine such trials involving a total of almost 20,000 patients confirmed this finding and also found that supplementation was associated with a slightly increased risk of gestational hypertension (relative risk [RR] 1.11, 95% CI 1.05-1.17), but this could have been the result of multiple statistical comparisons [
         <a href="#rid102">
          102,103
         </a>
         ]. Similarly, two trials included in a meta-analysis noted that supplementation was associated with an increased risk of prelabor rupture of membranes (RR 1.73, 95% CI 1.34-2.23) [
         <a href="#rid103">
          103
         </a>
         ] but not preterm prelabor rupture of membranes.
        </p>
        <p class="headingAnchor" id="H1714148905">
         <span class="h2">
          Vitamin D supplements
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2016 meta-analysis of vitamin D supplementation in pregnancy concluded supplementation may reduce the risk of preeclampsia (8.9 versus 15.5 percent, RR 0.52, 95% CI 0.25-1.05), but these findings were based on only two low-quality trials involving a total of 219 patients [
         <a href="#rid104">
          104
         </a>
         ]. The combination of vitamin D and calcium resulted in a lower risk of preeclampsia than not receiving this intervention (RR 0.51, 95% CI 0.32-0.80, three trials, 1114 patients, moderate quality), but this may have been related to calcium supplementation in calcium-deficient patients. A dose of 600 international units (the recommended dietary allowance) appears to be sufficient as it results in similar preeclampsia risk as higher doses [
         <a href="#rid105">
          105
         </a>
         ]. (See
         <a class="local">
          'Calcium supplementation'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3218062504">
         <span class="h2">
          Folic acid supplementation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The body of data does not indicate a consistent decreased or increased risk for hypertensive disorders of pregnancy (preeclampsia, gestational hypertension) with
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         supplementation [
         <a href="#rid106">
          106,107
         </a>
         ], even at high doses (4 mg daily) [
         <a href="#rid108">
          108
         </a>
         ]. Regardless, periconceptional folic acid supplementation is recommended to reduce the occurrence of neural tube defects. (See
         <a class="medical medical_review" href="/z/d/html/423.html" rel="external">
          "Preconception and prenatal folic acid supplementation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3981324651">
         <span class="h2">
          Fish oil supplements
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a 2018 Cochrane meta-analysis of randomized trials, compared with placebo or no marine omega-3 fatty acid intervention, marine omega-3 fatty acid supplementation (food, supplements) during pregnancy showed a trend toward a reduction in preeclampsia (RR 0.84, 95% CI 0.69-1.01, 20 trials, n &gt;8300 patients), but the evidence was low quality [
         <a href="#rid109">
          109
         </a>
         ]. When only trials at low risk of bias were analyzed, the trend disappeared (RR 1.00, 95% CI 0.81-1.25). In another review [
         <a href="#rid110">
          110
         </a>
         ], only three trials of marine omega-3 fatty acid supplementation in patients with singleton gestations at high risk of preeclampsia or growth restriction were considered well-designed, and none reported a reduction in these outcomes [
         <a href="#rid111">
          111-113
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1107388388">
         <span class="h2">
          Diet
         </span>
         <span class="headingEndMark">
          —
         </span>
         Only a few small randomized trials have evaluated the role of dietary modifications in the prevention of preeclampsia. No beneficial results have been demonstrated from these interventions, which include nutritional advice, protein and energy supplements, protein and energy restriction (in patients with obesity), magnesium supplementation, and salt restriction [
         <a href="#rid114">
          114-116
         </a>
         ].
        </p>
        <p>
         A systematic review of observational data suggested that dietary patterns higher in vegetables, fruits, whole grains, nuts, legumes, fish, and vegetable oils and lower in meat, refined grains, and added sugar were associated with reduced risk of preeclampsia and gestational hypertension [
         <a href="#rid117">
          117
         </a>
         ]. Although there are limitations in observational data, a healthy diet is beneficial over the long-term regardless of pregnancy status and not associated with any harms.
        </p>
        <p class="headingAnchor" id="H2749302556">
         <span class="h2">
          Nitric oxide donors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with preeclampsia may be deficient in nitric oxide, which mediates vasodilatation and inhibits platelet aggregation. However, a systematic review concluded that there is no high-quality evidence that administration of nitric oxide donors (
         <a class="drug drug_general" data-topicid="9706" href="/z/d/drug information/9706.html" rel="external">
          nitroglycerin
         </a>
         ) prevents preeclampsia [
         <a href="#rid118">
          118
         </a>
         ].
        </p>
        <p>
         L-arginine, the substrate for synthesis of nitric oxide, has been investigated as a means of preventing preeclampsia. In a small randomized trial that tested this approach in patients with a history of preeclampsia in a previous pregnancy (a group who would be expected to have a recurrence rate of between 5 and 20 percent), supplementation with medical food-bars containing L-arginine plus antioxidant vitamin was associated with a significant reduction in the incidence of preeclampsia compared with placebo (29 [13/228] versus 67 percent [30/222]; RR 0.17, 95% CI 0.12-0.21) and compared with use of antioxidant vitamins alone (29 [13/228] versus 50 percent [23/222]; RR 0.09, 95% CI 0.05-0.14) [
         <a href="#rid119">
          119
         </a>
         ]. The mean gestational age at delivery was &gt;38 weeks, regardless of treatment assignment, and there were no significant differences between groups in mean infant birth weight, proportion of SGA infants, or rate of abruption. Thus, it appears that most of these patients had mild preeclampsia, and the experimental treatment did not have an important impact on meaningful clinical outcomes.
        </p>
        <p class="headingAnchor" id="H341213269">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109729.html" rel="external">
          "Society guideline links: Hypertensive disorders of pregnancy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/6720.html" rel="external">
          "Patient education: Preeclampsia (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Low-dose
         </strong>
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         <strong>
          (preferred approach)
         </strong>
         – Low-dose aspirin reduces the risk of developing preterm preeclampsia. (See
         <a class="local">
          'Low-dose aspirin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Candidates
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients at high-risk of developing preeclampsia, we suggest low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         prophylaxis (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). At least a modest (≥10 percent) reduction in the overall incidence of preeclampsia and its sequelae (growth restriction, preterm birth) is possible. The risk for preterm preeclampsia is reduced more than that for term preeclampsia. We base our selection of high-risk patients on United States Preventive Services Task Force /American College of Obstetricians and Gynecologists criteria  (
         <a class="graphic graphic_table graphicRef142323" href="/z/d/graphic/142323.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Selecting patients at high risk of developing preeclampsia'
         </a>
         above and
         <a class="local">
          'Other considerations'
         </a>
         above and
         <a class="local">
          'Evidence of efficacy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         We do not prescribe low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for patients at low risk of developing preeclampsia (eg, healthy nulliparous patients) because pregnancy outcomes such as birth weight, fetal growth restriction, and length of gestation are similar to those in untreated patients. (See
         <a class="local">
          'Selecting patients at high risk of developing preeclampsia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/140781.html" rel="external">
          "Spontaneous preterm birth: Overview of interventions for risk reduction", section on 'Low-dose aspirin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Administration and dose
         </strong>
         – We use
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         81 mg daily for prevention of preeclampsia in patients at high risk. Emerging evidence suggests a benefit of doses of 100 to 150 mg, and possibly 162 mg. (See
         <a class="local">
          'Dose'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         We begin
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         in the 12
         <sup>
          th
         </sup>
         or 13
         <sup>
          th
         </sup>
         week of gestation and ideally prior to 16 weeks of gestation. We continue aspirin until delivery; some have suggested discontinuation at 36 weeks or 5 to 10 days prior to delivery to theoretically to diminish the risk of bleeding during delivery. (See
         <a class="local">
          'Timing of initiation'
         </a>
         above and
         <a class="local">
          'Timing of discontinuation'
         </a>
         above and
         <a class="local">
          'Safety'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         If
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         is not initiated at the end of the first trimester, initiation after 16 weeks (but before symptoms develop) may also be effective. (See
         <a class="local">
          'Timing of initiation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other approaches
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antihypertensive therapy for chronic hypertension
         </strong>
         – Treatment of mild chronic hypertension during pregnancy reduces the incidence of preeclampsia with severe features and development of severe hypertension. (See
         <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">
          "Treatment of hypertension in pregnant and postpartum patients"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116432.html" rel="external">
          "Chronic hypertension in pregnancy: Prenatal and postpartum care"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Calcium
         </strong>
         – In populations with low calcium intake, the World Health Organization recommends 1500 to 2000 mg elemental calcium supplementation per day for pregnant individuals to reduce the risk of preeclampsia, particularly those at higher risk of developing hypertension. For healthy females in the United States, we agree with the recommended daily allowance for elemental calcium advised in the United States: 1000 mg/day in pregnant and lactating individuals 19 to 50 years of age (1300 mg for girls 14 to 18 years old). We do not prescribe a higher intake via diet and/or supplements for patients at high risk of developing preeclampsia, as even 500 mg/day may be adequate for this purpose. (See
         <a class="local">
          'Calcium supplementation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preconception weight loss, appropriate gestational weight gain
         </strong>
         – Preconception weight loss and appropriate gestational weight gain can reduce the risk of developing preeclampsia. Weight loss in patients who are overweight or obese is recommended for a variety of reproductive, pregnancy, and health benefits. (See
         <a class="local">
          'Prepregnancy weight loss and appropriate gestational weight gain'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low molecular weight heparin
         </strong>
         – Available data do
         <strong>
          not
         </strong>
         conclusively support use of low molecular weight heparin prophylaxis in addition to low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         to reduce the risk of preeclampsia or its sequelae, although these data are not definitive, and there are methodologic concerns with the published trials. (See
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Timed birth at 39 weeks
         </strong>
         – In the ARRIVE trial, nulliparas assigned to induction of labor at 39+0 to 39+4 weeks of gestation were less likely to develop a hypertensive disorder of pregnancy than those assigned to expectant management until 40+5 to 42+2 weeks. Delivery at 39 weeks for this indication should be a shared decision. (See
         <a class="local">
          'Timed birth at 39 weeks in low-risk, nulliparous patients'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989; 321:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. N Engl J Med 1989; 321:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wallenburg HC, Dekker GA, Makovitz JW, Rotmans P. Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae. Lancet 1986; 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985; 1:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990; 335:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dekker GA, Sibai BM. Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials. Am J Obstet Gynecol 1993; 168:214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med 1991; 325:1137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrono C. Aspirin as an antiplatelet drug. N Engl J Med 1994; 330:1287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cadavid AP. Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications. Front Immunol 2017; 8:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JM, King TL, Barton JR, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. Am J Obstet Gynecol 2023; 229:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Meher S, Hunter KE, et al. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2019; 2019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright D, Rolnik DL, Syngelaki A, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol 2018; 218:612.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson JT, Vesco KK, Senger CA, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2021; 326:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2018; 218:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rolnik DL, Wright D, Poon LC, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge S, Nicolaides KH, Demers S, et al. Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis. Ultrasound Obstet Gynecol 2013; 41:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coomarasamy A, Honest H, Papaioannou S, et al. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101:1319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. Am J Obstet Gynecol 2017; 216:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; :CD004659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007; 369:1791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meher S, Alfirevic Z. Aspirin for pre-eclampsia: beware of subgroup meta-analysis. Ultrasound Obstet Gynecol 2013; 41:479.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henderson JT, Whitlock EP, O'Connor E, et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2014; 160:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge S, Nicolaides K, Demers S, et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           US Preventive Services Task Force, Davidson KW, Barry MJ, et al. Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement. JAMA 2021; 326:1186.
          </a>
         </li>
         <li class="breakAll">
          American College of Obstetricians and Gynecologists' Practice Advisory: Low-Dose Aspirin Use for the Prevention of Preeclampsia and Related Morbidity and Mortality. December 2021. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/12/low-dose-aspirin-use-for-the-prevention-of-preeclampsia-and-related-morbidity-and-mortality (Accessed on December 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hauspurg A, Sutton EF, Catov JM, Caritis SN. Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort. Hypertension 2018; 72:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Man R, Hodgetts Morton V, Devani P, Morris RK. Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2021; 262:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993; 329:1213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subtil D, Goeusse P, Puech F, et al. Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1). BJOG 2003; 110:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang Y, McIntosh JJ, Reese JA, et al. Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood 2014; 123:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vesely SK. Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost 2015; 13 Suppl 1:S216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown MA, Magee LA, Kenny LC, et al. Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice. Hypertension 2018; 72:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magee LA, Brown MA, Hall DR, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis &amp; management recommendations for international practice. Pregnancy Hypertens 2022; 27:148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabbay-Benziv R, Oliveira N, Baschat AA. Optimal first trimester preeclampsia prediction: a comparison of multimarker algorithm, risk profiles and their sequential application. Prenat Diagn 2016; 36:34.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skråstad RB, Hov GG, Blaas HG, et al. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms. BJOG 2015; 122:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akolekar R, Syngelaki A, Sarquis R, et al. Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks. Prenat Diagn 2011; 31:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park FJ, Leung CH, Poon LC, et al. Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy. Aust N Z J Obstet Gynaecol 2013; 53:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scazzocchio E, Figueras F, Crispi F, et al. Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting. Am J Obstet Gynecol 2013; 208:203.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994; 343:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiff E, Barkai G, Ben-Baruch G, Mashiach S. Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension. Obstet Gynecol 1990; 76:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paller MS. Hypertension in pregnancy. J Am Soc Nephrol 1998; 9:314.
          </a>
         </li>
         <li class="breakAll">
          Society of Obstetricians and Gynaecologists of Canada. SOGC clinical practice guideline No. 307. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: Executive summary. http://sogc.org/wp-content/uploads/2014/05/gui307CPG1405Erev.pdf (Accessed on July 27, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dentali F, Ageno W, Rezoagli E, et al. Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature. J Thromb Haemost 2012; 10:2075.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schisterman EF, Silver RM, Perkins NJ, et al. A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics. Paediatr Perinat Epidemiol 2013; 27:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poon LC, Shennan A, Hyett JA, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chaemsaithong P, Cuenca-Gomez D, Plana MN, et al. Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia? Am J Obstet Gynecol 2020; 222:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong S, Mol BW, Walker SP. Preventing preeclampsia with aspirin: does dose or timing matter? Am J Obstet Gynecol 2017; 216:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermida RC, Ayala DE, Calvo C, López JE. Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients. J Am Coll Cardiol 2005; 46:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wright D, Poon LC, Rolnik DL, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol 2017; 217:685.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navaratnam K, Alfirevic A, Jorgensen A, Alfirevic Z. Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2018; 221:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kini V, Ho PM. Interventions to Improve Medication Adherence: A Review. JAMA 2018; 320:2461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirsh J, Guyatt G, Albers GW, et al. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:71S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendoza M, Bonacina E, Garcia-Manau P, et al. Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial. JAMA 2023; 329:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberge S, Bujold E, Nicolaides KH. Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage. Am J Obstet Gynecol 2018; 218:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozer E, Nikfar S, Costei A, et al. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol 2002; 187:1623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naimi AI, Perkins NJ, Sjaarda LA, et al. The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial. Ann Intern Med 2021; 174:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landman AJEMC, van Limburg Stirum EVJ, de Boer MA, et al. Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol 2021; 267:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tita AT, Szychowski JM, Boggess K, et al. Treatment for Mild Chronic Hypertension during Pregnancy. N Engl J Med 2022; 386:1781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grobman WA, Rice MM, Reddy UM, et al. Labor Induction versus Expectant Management in Low-Risk Nulliparous Women. N Engl J Med 2018; 379:513.
          </a>
         </li>
         <li class="breakAll">
          Food Surveys Research Group. Dietary date brief No. 13. Calcium intake of the US population: What we eat in America NHANES 2009-2010. https://www.ars.usda.gov/ARSUserFiles/80400530/pdf/DBrief/13_calcium_intake_0910.pdf (Accessed on November 28, 2017).
         </li>
         <li class="breakAll">
          World Health Organization. WHO guideline: Calcium supplementation in pregnant women. http://apps.who.int/iris/bitstream/10665/85120/1/9789241505376_eng.pdf?ua=1 (Accessed on January 20, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo Kinshella ML, Sarr C, Sandhu A, et al. Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care. BJOG 2022; 129:1833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dwarkanath P, Muhihi A, Sudfeld CR, et al. Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy. N Engl J Med 2024; 390:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300:2286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mostello D, Jen Chang J, Allen J, et al. Recurrent preeclampsia: the effect of weight change between pregnancies. Obstet Gynecol 2010; 116:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robillard PY, Dekker G, Scioscia M, et al. Preeclampsia in 2023: Time for preventing early onset- and term preeclampsia: The paramount role of gestational weight gain. J Reprod Immunol 2023; 158:103968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davenport MH, Ruchat SM, Poitras VJ, et al. Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis. Br J Sports Med 2018; 52:1367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Danielli M, Gillies C, Thomas RC, et al. Effects of Supervised Exercise on the Development of Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis. J Clin Med 2022; 11.
          </a>
         </li>
         <li class="breakAll">
          https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy. (Accessed on July 21, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bauer AJ, Banek CT, Needham K, et al. Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension. Hypertension 2013; 61:1103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011; 205:366.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saad AF, Kechichian T, Yin H, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci 2014; 21:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model. Proc Natl Acad Sci U S A 2011; 108:1451.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ahmed A, Singh J, Khan Y, et al. A new mouse model to explore therapies for preeclampsia. PLoS One 2010; 5:e13663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 2016; 214:720.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Döbert M, Varouxaki AN, Mu AC, et al. Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia. Circulation 2021; 144:670.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wei J, Liao JK, Bairey Merz CN. Challenging Statin Pleiotropy: Preeclampsia. Circulation 2021; 144:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alfirevic Z, Roberts D, Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur J Obstet Gynecol Reprod Biol 2002; 101:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin J, August P. Genetic thrombophilias and preeclampsia: a meta-analysis. Obstet Gynecol 2005; 105:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mello G, Parretti E, Marozio L, et al. Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study. Hypertension 2005; 46:1270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Facchinetti F, Marozio L, Frusca T, et al. Maternal thrombophilia and the risk of recurrence of preeclampsia. Am J Obstet Gynecol 2009; 200:46.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mello G, Parretti E, Fatini C, et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension 2005; 45:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodger MA, Gris JC, de Vries JIP, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet 2016; 388:2629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Areia AL, Fonseca E, Areia M, Moura P. Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. Arch Gynecol Obstet 2016; 293:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haddad B, Winer N, Chitrit Y, et al. Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial. Obstet Gynecol 2016; 128:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groom KM, McCowan LM, Mackay LK, et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol 2017; 216:296.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Syngelaki A, Nicolaides KH, Balani J, et al. Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus. N Engl J Med 2016; 374:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alqudah A, McKinley MC, McNally R, et al. Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis. Diabet Med 2018; 35:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feig DS, Donovan LE, Zinman B, et al. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2020; 8:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tong S, Kaitu'u-Lino TJ, Hastie R, et al. Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia. Am J Obstet Gynecol 2022; 226:S1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beazley D, Ahokas R, Livingston J, et al. Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial. Am J Obstet Gynecol 2005; 192:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poston L, Briley AL, Seed PT, et al. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006; 367:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rumbold AR, Crowther CA, Haslam RR, et al. Vitamins C and E and the risks of preeclampsia and perinatal complications. N Engl J Med 2006; 354:1796.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spinnato JA 2nd, Freire S, Pinto E Silva JL, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 2007; 110:1311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villar J, Purwar M, Merialdi M, et al. World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries. BJOG 2009; 116:780.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xu H, Perez-Cuevas R, Xiong X, et al. An international trial of antioxidants in the prevention of preeclampsia (INTAPP). Am J Obstet Gynecol 2010; 202:239.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2010; 362:1282.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCance DR, Holmes VA, Maresh MJ, et al. Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial. Lancet 2010; 376:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Basaran A, Basaran M, Topatan B. Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis. Obstet Gynecol Surv 2010; 65:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conde-Agudelo A, Romero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 204:503.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De-Regil LM, Palacios C, Lombardo LK, Peña-Rosas JP. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2016; :CD008873.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palacios C, Trak-Fellermeier MA, Martinez RX, et al. Regimens of vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev 2019; 10:CD013446.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shim SM, Yun YU, Kim YS. Folic acid alone or multivitamin containing folic acid intake during pregnancy and the risk of gestational hypertension and preeclampsia through meta-analyses. Obstet Gynecol Sci 2016; 59:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hua X, Zhang J, Guo Y, et al. Effect of folic acid supplementation during pregnancy on gestational hypertension/preeclampsia: A systematic review and meta-analysis. Hypertens Pregnancy 2016; 35:447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wen SW, White RR, Rybak N, et al. Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial. BMJ 2018; 362:k3478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. Cochrane Database Syst Rev 2018; 11:CD003402.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saccone G, Saccone I, Berghella V. Omega-3 long-chain polyunsaturated fatty acids and fish oil supplementation during pregnancy: which evidence? J Matern Fetal Neonatal Med 2016; 29:2389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olsen SF, Secher NJ, Tabor A, et al. Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team. BJOG 2000; 107:382.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulstra-Ramakers MT, Huisjes HJ, Visser GH. The effects of 3g eicosapentaenoic acid daily on recurrence of intrauterine growth retardation and pregnancy induced hypertension. Br J Obstet Gynaecol 1995; 102:123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Onwude JL, Lilford RJ, Hjartardottir H, et al. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol 1995; 102:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villar J, Abalos E, Nardin JM, et al. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. Semin Nephrol 2004; 24:607.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duley L, Henderson-Smart D, Meher S. Altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev 2005; :CD005548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Briceño-Pérez C, Briceño-Sanabria L, Vigil-De Gracia P. Prediction and prevention of preeclampsia. Hypertens Pregnancy 2009; 28:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raghavan R, Dreibelbis C, Kingshipp BL, et al. Dietary patterns before and during pregnancy and maternal outcomes: a systematic review. Am J Clin Nutr 2019; 109:705S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meher S, Duley L. Nitric oxide for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007; :CD006490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ 2011; 342:d2901.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6817 Version 104.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2664523" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2664522" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2867260" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Low-dose aspirin prevents pregnancy-induced hypertension and pre-eclampsia in angiotensin-sensitive primigravidae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2858710" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevention of pre-eclampsia by early antiplatelet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1972487" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8420330" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Low-dose aspirin in the prevention of preeclampsia and fetal growth retardation: rationale, mechanisms, and clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1891022" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8145785" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Aspirin as an antiplatelet drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28360907" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37120055" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31684684" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antiplatelet agents for preventing pre-eclampsia and its complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29505771" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34581730" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29138036" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28657417" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23362106" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12798543" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27810551" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443552" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Antiplatelet agents for preventing pre-eclampsia and its complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17512048" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23610032" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Aspirin for pre-eclampsia: beware of subgroup meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24711050" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27640943" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34581729" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29802215" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Aspirin Effect on Adverse Pregnancy Outcomes Associated With Stage 1 Hypertension in a High-Risk Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34010722" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Aspirin for preventing adverse outcomes in low risk nulliparous women with singleton pregnancies: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8413387" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12742332" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Aspirin (100 mg) used for prevention of pre-eclampsia in nulliparous women: the Essai Régional Aspirine Mère-Enfant study (Part 1).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24398329" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26149027" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29899139" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hypertensive Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management Recommendations for International Practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35066406" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis&amp;management recommendations for international practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26448637" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Optimal first trimester preeclampsia prediction: a comparison of multimarker algorithm, risk profiles and their sequential application.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25471057" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21210481" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Prediction of early, intermediate and late pre-eclampsia from maternal factors, biophysical and biochemical markers at 11-13 weeks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23919594" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Clinical evaluation of a first trimester algorithm predicting the risk of hypertensive disease of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23246313" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Performance of a first-trimester screening of preeclampsia in a routine care low-risk setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7906809" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2216216" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Low-dose aspirin does not influence the clinical course of women with mild pregnancy-induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20739360" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Management of hypertensive disorders during pregnancy: summary of NICE guidance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527410" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Hypertension in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9527410" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Hypertension in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22900525" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Low-dose aspirin for in vitro fertilization or intracytoplasmic sperm injection: a systematic review and a meta-analysis of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24118062" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31111484" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31494125" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Does low-dose aspirin initiated before 11 weeks' gestation reduce the rate of preeclampsia?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28148451" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Preventing preeclampsia with aspirin: does dose or timing matter?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23004922" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Chronotherapy with low-dose aspirin for prevention of complications in pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16168278" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Aspirin administered at bedtime, but not on awakening, has an effect on ambulatory blood pressure in hypertensive patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28888591" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29304392" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Aspirin non-responsiveness in pregnant women at high-risk of pre-eclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30561486" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Interventions to Improve Medication Adherence: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18574259" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36809321" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29305829" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Meta-analysis on the effect of aspirin use for prevention of preeclampsia on placental abruption and antepartum hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12501074" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33493011" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The Effect of Preconception-Initiated Low-Dose Aspirin on Human Chorionic Gonadotropin-Detected Pregnancy, Pregnancy Loss, and Live Birth : Per Protocol Analysis of a Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34826669" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Long-term health and neurodevelopment in children after antenatal exposure to low-dose aspirin for the prevention of preeclampsia and fetal growth restriction: A systematic review of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35363951" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Treatment for Mild Chronic Hypertension during Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30089070" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Labor Induction versus Expectant Management in Low-Risk Nulliparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30089070" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Labor Induction versus Expectant Management in Low-Risk Nulliparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30089070" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Labor Induction versus Expectant Management in Low-Risk Nulliparous Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35596262" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38197817" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19017915" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pregnancy and fertility following bariatric surgery: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733450" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Recurrent preeclampsia: the effect of weight change between pregnancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37290173" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Preeclampsia in 2023: Time for preventing early onset- and term preeclampsia: The paramount role of gestational weight gain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30337463" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Prenatal exercise for the prevention of gestational diabetes mellitus and hypertensive disorders of pregnancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35160245" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Effects of Supervised Exercise on the Development of Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35160245" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Effects of Supervised Exercise on the Development of Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460290" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Pravastatin attenuates hypertension, oxidative stress, and angiogenic imbalance in rat model of placental ischemia-induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22083058" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23749761" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21187414" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Pravastatin induces placental growth factor (PGF) and ameliorates preeclampsia in a mouse model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21048973" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A new mouse model to explore therapies for preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26723196" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34162218" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pravastatin Versus Placebo in Pregnancies at High Risk of Term Preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34460319" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Challenging Statin Pleiotropy: Preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11803092" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15625161" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Genetic thrombophilias and preeclampsia: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16246971" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Thrombophilia is significantly associated with severe preeclampsia: results of a large-scale, case-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18845284" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Maternal thrombophilia and the risk of recurrence of preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19036070" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15557391" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27720497" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26059084" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27741174" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28153659" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26840133" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29044702" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Risk of pre-eclampsia in women taking metformin: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32946820" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32946849" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15695996" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Vitamin C and E supplementation in women at high risk for preeclampsia: a double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16616557" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16641396" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Vitamins C and E and the risks of preeclampsia and perinatal complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18055726" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Antioxidant therapy to prevent preeclampsia: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19432566" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : World Health Organisation multicentre randomised trial of supplementation with vitamins C and E among pregnant women at high risk for pre-eclampsia in populations of low nutritional status from developing countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20207239" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : An international trial of antioxidants in the prevention of preeclampsia (INTAPP).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20375405" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Vitamins C and E to prevent complications of pregnancy-associated hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20580423" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21182804" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Combined vitamin C and E supplementation for the prevention of preeclampsia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21529757" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765344" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Vitamin D supplementation for women during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31581312" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Regimens of vitamin D supplementation for women during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27004201" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Folic acid alone or multivitamin containing folic acid intake during pregnancy and the risk of gestational hypertension and preeclampsia through meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27315401" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Effect of folic acid supplementation during pregnancy on gestational hypertension/preeclampsia: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30209050" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30480773" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Omega-3 fatty acid addition during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26382010" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Omega-3 long-chain polyunsaturated fatty acids and fish oil supplementation during pregnancy: which evidence?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10740336" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756203" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : The effects of 3g eicosapentaenoic acid daily on recurrence of intrauterine growth retardation and pregnancy induced hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7756226" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : A randomised double blind placebo controlled trial of fish oil in high risk pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15529296" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16235411" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Altered dietary salt for preventing pre-eclampsia, and its complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19437225" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Prediction and prevention of preeclampsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30982868" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Dietary patterns before and during pregnancy and maternal outcomes: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17443623" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Nitric oxide for preventing pre-eclampsia and its complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21596735" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
